Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India
NCT04588402 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5500
Last updated 2026-04-03
Summary
This project aims is to monitor the effectiveness of HPV vaccination in real-word conditions, at least 7 years after initiation of HPV vaccination in Sikkim. This study would give an opportunity to provide rapid feedback to the Indian public health authorities about the impact of the HPV vaccine.
Conditions
Interventions
- BIOLOGICAL
-
The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals.
Women will be approached one time only, when they will attend the gynecology out-patients department for various reasons. After signing the informed consent, the participants will fill in a risk factor questionnaire to study the socio-demographic information, sexual history and HPV vaccination history and the determinent of HPV infection. The questionnaire will be administered by a trained social worker or nurse. A gynecologist will collect cervical cells from the participant's cervix during a gynecological examination. The cervical specimen will be examined for presence of specific HPV genotypes and Chlamydia infection.
Sponsors & Collaborators
-
Department of Health and Family welfare, Government of Sikkim
collaborator UNKNOWN -
Sikkim Manipal Institute
collaborator UNKNOWN -
Rajiv Gandhi Centre for Biotechnology
collaborator INDUSTRY -
International Agency for Research on Cancer
lead OTHER
Principal Investigators
-
Yogesh Verma, MD · Sikkim Manipal Inst., Sikkim, India
-
Phumzay Denzongpa, MD · Dept of H & FW, Govt. of Sikkim, India
Eligibility
- Min Age
- 18 Years
- Max Age
- 22 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-10-01
- Primary Completion
- 2026-10-30
- Completion
- 2026-12-31
Countries
- India
Study Locations
More Related Trials
-
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
NCT01021904 ·Status: UNKNOWN ·Phase: PHASE4
-
Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical Cancer
NCT01221987 ·Status: COMPLETED
-
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
NCT02934724 ·Status: COMPLETED
-
A Multicenter Cohort Study Assessing the Efficacy and Adverse Effects of HPV Vaccination in Chinese Women
NCT05932576 ·Status: UNKNOWN
-
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
NCT00481767 ·Status: COMPLETED ·Phase: PHASE3
-
Cervical Cancer Screening by Self-sampling in a Cohort of Younger Women in Ethiopia
NCT05125380 ·Status: RECRUITING ·Phase: NA
-
Multimodality Treatments of HPV-related Lesions of the Female Genital Tract
NCT05938192 ·Status: RECRUITING
-
Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda
NCT06536855 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study
NCT02323997 ·Status: COMPLETED
-
A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea
NCT03671369 ·Status: COMPLETED
-
Effect of HPV Vaccination on Women Aged 25 Years
NCT02296255 ·Status: COMPLETED ·Phase: PHASE4
-
Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer
NCT00002916 ·Status: COMPLETED ·Phase: PHASE2
-
Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China
NCT01487681 ·Status: UNKNOWN
-
Effectiveness of Targeted Educational Interventions at Increasing HPV Vaccine Acceptability and Uptake
NCT03337269 ·Status: COMPLETED ·Phase: NA
-
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
NCT00121173 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
NCT00667563 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety Study of NBP615 in Healthy Female
NCT04453241 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
NCT00054041 ·Status: COMPLETED ·Phase: PHASE2
-
Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand
NCT01328028 ·Status: COMPLETED
-
Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
NCT05640700 ·Status: RECRUITING
-
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
NCT00988559 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age
NCT05838157 ·Status: UNKNOWN
-
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
NCT00518336 ·Status: COMPLETED ·Phase: PHASE2
-
In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer?
NCT02937155 ·Status: UNKNOWN
-
Impact of HPV Vaccination to Catch up in the Emergence of Lesions of the Cervix
NCT03328013 ·Status: TERMINATED